Parkinson’s Disease

DelveInsight has launched a new report on Parkinson’s Disease Market Insights, Epidemiology and Market Forecast-2030

The Parkinson’s Disease market report provides current treatment practices, emerging drugs, Parkinson’s Disease market share of the individual therapies, current and forecasted Parkinson’s Disease Pain market Size from 2017 to 2030 segmented by seven major markets. The Report also covers current Parkinson’s Disease treatment practice/algorithm, market drivers, market barriers and unmet medical needs to curate best of the opportunities and assesses the underlying potential of the market.

Key benefits of the report
1. Parkinson’s Disease market report covers a descriptive overview and comprehensive insight of the Parkinson’s Disease epidemiology and Parkinson’s Disease market in the 7 MM (the United States, EU5 (Germany, Spain, France, Italy, UK) & Japan.) 
2. Parkinson’s Disease market report provides insights on the current and emerging therapies.
3. Parkinson’s Disease market report provides a global historical and forecasted market covering drug outreach in 7 MM.   
4. Parkinson’s Disease market report offers an edge that will help in developing business strategies by understanding trends shaping and driving the Parkinson’s Disease market.

Request for sample pages here -> https://www.delveinsight.com/sample-request/parkinsons-disease-market-size-analysis-treatment

Parkinson’s disease is a type of movement disorder that can affect the ability to perform common, daily activities. The most common motor symptoms of PD are tremor (a form of rhythmic shaking), stiffness or rigidity of the muscles, and slowness of movement (called bradykinesia).

Most of the people develop the symptoms of Parkinson’s after the age of 50, but it can affect younger person as well.

There are mainly two types of Parkinson’s, Primary Parkinsonism or Idiopathic Parkinson’s and Secondary or atypical Parkinsonism.

Parkinson’s disease as a progressive disorder that is caused by degeneration of nerve cells in the part of the brain called the substantia nigra, which controls movement. Most people with Parkinson’s start to develop symptoms when they’re over 50, although around one in 20 people with the condition first experience symptoms when they’re under 40.

Drugs covered

1. 1.           Apomorphine Infusion
2. 2.          Accordion Pill Carbidopa/Levodopa
3. 3.           APL–130277
4. 4.          P2B001
5. 5.           IPX203
6. 6.           LY03003
7. 7.          ABBV-951

And many others

The key players in Parkinson’s Disease market are:

1. US WorldMeds LLC
2. Intec Pharma
3. Sunovion Pharma
4. Pharma Two B Ltd
5. Impax Laboratories
6. Luye Pharma
7. AbbVie

And many others

Table of contents

1. Key Insights

2. Parkinson’s Disease Market Overview at a Glance

3. Parkinson’s Disease Background and Overview

4. Parkinson’s Disease Epidemiology and Patient Population

5. Country Wise Parkinson’s Disease Epidemiology

5.1. United States Epidemiology

5.2. EU-5 Epidemiology

5.2.1. Germany

5.2.2. France

5.2.3. Italy

5.2.4. Spain

5.2.5. United Kingdom

5.3. Japan Epidemiology

6. Parkinson’s Disease Treatment and Management

7. Unmet Needs

8. Parkinson’s Disease Marketed Drugs

8.1. Key Cross of Marketed Drugs

8.2. Profiles of Some of the Marketed Drugs

8.3. Istradefylline (KW6002): Kyowa Kirin

8.4. Opicapone: BIAL

8.5. Gocovri: Adamas Pharmaceuticals

8.6. Xadago: Zambon SpA

8.7. Osmolex ER: Osmotica Pharmaceutical

8.8. Duopa (Duodopa, ABT-SLV187): AbbVie

8.9. Rytary: Impax Laboratories

8.10. Inbrija: Acorda Therapeutics

8.11. Nuplazid: ACADIA Pharmaceuticals Inc.

9. Parkinson’s Disease Emerging Drugs

9.1. Key Cross of Emerging Drugs

9.2. Apomorphine Infusion: US WorldMeds LLC

9.3. Accordion Pill Carbidopa/Levodopa: Intec Pharma

9.4. APL–130277: Sunovion Pharma

9.5. P2B001: Pharma Two B Ltd.

9.6. IPX203: Impax Laboratories

9.7. LY03003: Luye Pharma

9.8. ABBV-951: AbbVie

9.9. NTCELL Implantation: Living Cell Technologies

9.10. Nilotinib: Novartis

9.11. Solriamfetol (JZP-110): Jazz Pharmaceuticals

9.11.1. Product Description

9.11.2. Other Developmental Activities

9.11.3. Clinical Development

9.12. VY-AADC: Neurocrine Biosciences/Voyager Therapeutics

9.13. OXB-102 (AXO-Lenti-PD): Axovant Sciences

9.14. ND0612: NeuroDerm

9.15. ITI-214: Intracellular Therapies

9.16. IRL752: Integrative Research Laboratories AB (IRLAB)

10. Parkinson’s Disease 7 Major Market Analysis

11. Market Outlook: The United States

11.1. United States Market Size

11.2. Market Outlook: Europe

11.2.1. Germany

11.2.2. France

11.2.3. Italy

11.2.4. Spain

11.2.5. United Kingdom

11.3. Market Outlook: Japan

12. Market Drivers

13. Market Barriers

14. SWOT Analysis

15. Appendix

16. DelveInsight Capabilities

17. Disclaimer

18. About DelveInsight

Request for sample pages here -> https://www.delveinsight.com/sample-request/parkinsons-disease-market-size-analysis-treatment

Related Reports:

Parkinson’s Disease – Pipeline Insights, 2020

Parkinson’s Disease Pipeline Insight, 2020 report by DelveInsight outlays comprehensive insights of present clinical development scenario and growth prospects across the Parkinson’s Disease market.

Parkinson’s Disease – Epidemiology Forecast to 2030

DelveInsight’s Parkinson’s Disease – Epidemiology Forecast 2030 report delivers an in-depth understanding of the disease, historical, and forecasted epidemiology of Parkinson’s Disease in the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan.

Media Contact
Company Name: DelveInsight
Contact Person: Priya Maurya
Email: Send Email
Phone: +919650213330
City: Albany
State: New York
Country: United States
Website: https://www.delveinsight.com/